sulfisomidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-infectives, sulfonamides 2526 515-64-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulfasomidine
  • sulfadimetine
  • sulfaisodimerazine
  • sulfamethine
  • sulfasomidin
  • sulfisomidin
  • sulfisomidine
  • sulphasomidine
  • sulphisomidine
  • sulfaisodimidine
A sulfanilamide antibacterial agent.
  • Molecular weight: 278.33
  • Formula: C12H14N4O2S
  • CLOGP: 1.10
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 97.97
  • ALOGS: -3.09
  • ROTB: 2

Drug dosage:

DoseUnitRoute
4 g O
4 g P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.443 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.243 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 5.662 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 1.074 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 43.930 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 53.850 % Moderate 0.65
herg hERG pIC50 3.945 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 1.312 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 3.184 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 32.980 % Moderate 0.65
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,JAK1,JAK2,KIT,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PAK4,PDK1,PDK2,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 52
kinase-selectivity-class ACVR2A,AURKA,AXL,CDK1,DDR1,DYRK1B,FGFR1,GRK2,MAP2K6,MAPK7,MARK4,PRKDC,SIK2,SIK3,STK33,SYK,TEK,ULK1 18
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.312 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 2.512 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 64.110 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.051 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 54.710 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 1.019 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.780 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 25.220 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 952.796 uM Moderate 0.65

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Joint dislocation 187.45 52.18 98 11412 44484 90572453
Hypercholesterolaemia 170.81 52.18 124 11386 100768 90516169
Hepatic cirrhosis 150.52 52.18 96 11414 63157 90553780
Seronegative arthritis 144.29 52.18 62 11448 18172 90598765
Joint stiffness 139.10 52.18 99 11411 77943 90538994
Anti-cyclic citrullinated peptide antibody 138.22 52.18 68 11442 27153 90589784
Lupus vulgaris 113.71 52.18 71 11439 44988 90571949
Grip strength decreased 113.46 52.18 94 11416 92482 90524455
Walking aid user 113.10 52.18 65 11445 35441 90581496
Retinitis 110.89 52.18 66 11444 38392 90578545
Prescribed underdose 110.80 52.18 85 11425 74934 90542003
Adjustment disorder with depressed mood 110.44 52.18 76 11434 56677 90560260
Foot deformity 109.34 52.18 77 11433 59574 90557363
Dislocation of vertebra 109.03 52.18 75 11435 55893 90561044
Bone erosion 107.91 52.18 73 11437 52948 90563989
Exostosis 107.77 52.18 73 11437 53061 90563876
Lupus-like syndrome 103.60 52.18 69 11441 48777 90568160
Deep vein thrombosis postoperative 101.87 52.18 79 11431 70730 90546207
Laryngitis 101.19 52.18 69 11441 50684 90566253
Hip arthroplasty 96.75 52.18 79 11431 76129 90540808
Autoimmune disorder 94.17 52.18 78 11432 76666 90540271
Osteoporosis 92.08 52.18 85 11425 96446 90520491
Drug ineffective 91.93 52.18 31 11479 1384267 89232670
Ear infection 89.98 52.18 73 11437 69702 90547235
Joint range of motion decreased 88.14 52.18 97 11413 135546 90481391
Disability 87.46 52.18 58 11452 40687 90576250
Wound infection 85.05 52.18 85 11425 106317 90510620
Spinal fusion surgery 81.77 52.18 37 11473 12246 90604691
Helicobacter infection 78.95 52.18 119 11391 226731 90390206
Impaired healing 78.89 52.18 121 11389 234078 90382859
Hypoaesthesia 78.60 52.18 142 11368 314068 90302869
Sciatica 77.38 52.18 79 11431 101303 90515634
Drug-induced liver injury 73.74 52.18 73 11437 90245 90526692
Spondylitis 73.69 52.18 36 11474 14142 90602795
Road traffic accident 73.45 52.18 79 11431 107547 90509390
Osteoarthritis 72.87 52.18 106 11404 195624 90421313
Injury 72.20 52.18 106 11404 197243 90419694
Delirium 71.91 52.18 77 11433 104282 90512655
Liver function test increased 71.91 52.18 70 11440 84785 90532152
Knee arthroplasty 67.47 52.18 67 11443 83115 90533822
Amnesia 66.01 52.18 75 11435 108430 90508507
Fibromyalgia 64.47 52.18 103 11407 206166 90410771
Type 2 diabetes mellitus 62.85 52.18 101 11409 203143 90413794
Gait inability 61.43 52.18 84 11426 146372 90470565
Irritable bowel syndrome 61.31 52.18 101 11409 207347 90409590
Lower limb fracture 60.82 52.18 64 11446 84949 90531988
Upper respiratory tract infection 60.59 52.18 78 11432 128240 90488697
Prescribed overdose 60.26 52.18 68 11442 97557 90519380
Red blood cell sedimentation rate increased 58.76 52.18 62 11448 82533 90534404
Visual impairment 58.68 52.18 78 11432 132287 90484650
Pulmonary fibrosis 56.58 52.18 69 11441 107434 90509503
C-reactive protein increased 55.88 52.18 90 11420 181299 90435638
Blood cholesterol increased 53.21 52.18 95 11415 207917 90409020

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sleep disorder due to general medical condition, insomnia type 47.40 33.04 31 2806 105612 110480850
Sciatica 46.12 33.04 29 2808 92370 110494092
Road traffic accident 42.14 33.04 29 2808 107369 110479093
Fibromyalgia 36.13 33.04 32 2805 170877 110415585
Type 2 diabetes mellitus 35.12 33.04 32 2805 177200 110409262
Helicobacter infection 34.41 33.04 32 2805 181845 110404617

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01EB01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
SULFONAMIDES AND TRIMETHOPRIM
Short-acting sulfonamides
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent

Related Drugs by ATC class:

J01EB Short-acting sulfonamides 7 drugs
sulfadimidinesulfafurazolesulfamethizolesulfanilamidesulfapyridinesulfathiazolesulfathiourea

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.21 acidic
pKa2 4.49 Basic
pKa3 2.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein argonaute-2 Enzyme Kd 5.37 CHEMBL

External reference:

IDSource
N0000166865 NUI
D01526 KEGG_DRUG
CHEBI:32166 CHEBI
CHEMBL485696 ChEMBL_ID
99 INN_ID
DB13283 DRUGBANK_ID
W03L3ODK6E UNII
10206 RXNORM
002823 NDDF
4014000 SNOMEDCT_US
C0038744 UMLSCUI
D013443 MESH_DESCRIPTOR_UI
5343 PUBCHEM_CID

Pharmaceutical products:

None